130 related articles for article (PubMed ID: 11961068)
1. Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy.
Di Stefano G; Lanza M; Busi C; Barbieri L; Fiume L
J Pharmacol Exp Ther; 2002 May; 301(2):638-42. PubMed ID: 11961068
[TBL] [Abstract][Full Text] [Related]
2. Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases.
Di Stefano G; Busi C; Fiume L
Dig Liver Dis; 2002 Jun; 34(6):439-46. PubMed ID: 12132792
[TBL] [Abstract][Full Text] [Related]
3. Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-L-lysine coupling: implications for regional chemotherapy of hepatic micrometastases.
Di Stefano G; Busi C; Camerino A; Nardo B; Fiume L
Biochem Pharmacol; 2000 Feb; 59(3):301-4. PubMed ID: 10609559
[TBL] [Abstract][Full Text] [Related]
4. Coupling of 5-fluoro 2'-deoxyuridine to lactosaminated poly-l-lysine: an approach to a regional, non-invasive chemotherapy of liver micrometastases.
Di Stefano G; Busi C; Camerino A; Derenzini M; Trerè D; Fiume L
Biochem Pharmacol; 2001 Feb; 61(4):459-65. PubMed ID: 11226380
[TBL] [Abstract][Full Text] [Related]
5. Lactosaminated human albumin, a hepatotropic carrier of drugs.
Fiume L; Di Stefano G
Eur J Pharm Sci; 2010 Jul; 40(4):253-62. PubMed ID: 20403430
[TBL] [Abstract][Full Text] [Related]
6. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor.
Fiume L; Di Stefano G; Busi C; Mattioli A; Bonino F; Torrani-Cerenzia M; Verme G; Rapicetta M; Bertini M; Gervasi GB
J Viral Hepat; 1997; 4(6):363-70. PubMed ID: 9430355
[TBL] [Abstract][Full Text] [Related]
7. Liver targeting of nucleoside analogues coupled to galactosyl terminating macromolecules: a new approach to the treatment of a chronic viral hepatitis.
Fiume L; Verme G
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):275-80. PubMed ID: 9646223
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas.
Di Stefano G; Busi C; Derenzini M; Trerè D; Fiume L
Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):173-7. PubMed ID: 9675653
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2',2'-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine.
Di Stefano G; Busi C; Mattioli A; Derenzini M; Trerè D; Fiume L
Biochem Pharmacol; 1999 Apr; 57(7):793-9. PubMed ID: 10075085
[TBL] [Abstract][Full Text] [Related]
10. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route.
Di Stefano G; Busi C; Mattioli A; Fiume L
Biochem Pharmacol; 1995 Jun; 49(12):1769-75. PubMed ID: 7541203
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and physicochemical characteristics of a liver-targeted conjugate of fluorodeoxyuridine monophosphate with lactosaminated human albumin.
Di Stefano G; Tubaro M; Lanza M; Boga C; Fiume L; Traldi P
Rapid Commun Mass Spectrom; 2003; 17(22):2503-7. PubMed ID: 14608620
[TBL] [Abstract][Full Text] [Related]
12. Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to specific uptake in rat and human hepatocytes.
Jansen RW; Kruijt JK; van Berkel TJ; Meijer DK
Hepatology; 1993 Jul; 18(1):146-52. PubMed ID: 7686877
[TBL] [Abstract][Full Text] [Related]
13. Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin.
Fiume L; Busi C; Di Stefano G; Mattioli A; Torrani-Cerenzia M; Bonino F; Capra G; De Bernardi W; Ponzetto A; Lavezzo B
Ital J Gastroenterol; 1995 May; 27(4):189-92. PubMed ID: 8520036
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier.
Di Stefano G; Kratz F; Lanza M; Fiume L
Dig Liver Dis; 2003 Jun; 35(6):428-33. PubMed ID: 12868680
[TBL] [Abstract][Full Text] [Related]
15. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
16. Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver.
Fiume L; Mattioli A; Busi C; Accorsi C
Gut; 1984 Dec; 25(12):1392-8. PubMed ID: 6210232
[TBL] [Abstract][Full Text] [Related]
17. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat.
Fiume L; Busi C; Preti P; Spinosa G
Cancer Drug Deliv; 1987; 4(3):145-50. PubMed ID: 2453263
[TBL] [Abstract][Full Text] [Related]
18. Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters.
Fiume L; Busi C; Di Stefano G; Mattioli A
Anal Biochem; 1993 Aug; 212(2):407-11. PubMed ID: 7692761
[TBL] [Abstract][Full Text] [Related]
19. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
Franssen EJ; Jansen RW; Vaalburg M; Meijer DK
Biochem Pharmacol; 1993 Mar; 45(6):1215-26. PubMed ID: 8466542
[TBL] [Abstract][Full Text] [Related]
20. Targeting of antiviral drugs by coupling with protein carriers.
Fiume L; Busi C; Mattioli A
FEBS Lett; 1983 Mar; 153(1):6-10. PubMed ID: 6186534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
